tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Tolba RH et al. Conversion to Neoral for tacrolimus-related adverse effects in liver transplant recipients and improvement in quality of life. 2001 Nov-Dec Transplant. Proc. pmid:11750475
Ferraresso M et al. Conversion from cyclosporine to tacrolimus for refractory acute rejection in pediatric kidney transplant recipients: a single-center experience. 2001 Nov-Dec Transplant. Proc. pmid:11750525
Rostaing L et al. Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. 1998 Transplant. Proc. pmid:9636520
Morris-Stiff G et al. Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636521
Yashima J et al. Successful conversion from tacrolimus to cyclosporine after kidney transplantation. 2000 Transplant. Proc. pmid:11119895
Corry RJ et al. Pancreas transplantation without antibody therapy. 1998 Transplant. Proc. pmid:9532050
Barrera-Pulido L et al. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications. 2009 Jul-Aug Transplant. Proc. pmid:19715870
Machado PG et al. Use of reduced dose of OKT3 (2.5 mg) after renal transplantation. 2002 Transplant. Proc. pmid:11959207
Sugioka A et al. FK 506 inhibits tolerance induction in mice liver transplantation. 2005 Jan-Feb Transplant. Proc. pmid:15808576
Lemmens HP et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. 1994 Transplant. Proc. pmid:7527983
Propper DJ et al. Effects of the immunosuppressive macrolides rapamycin and FK 506 in high responder rats presensitized to major histocompatibility complex antigens. 1993 Transplant. Proc. pmid:7679837
Jain AB et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721270
Okamura N et al. Enhanced liver regeneration by FK 506 can be blocked by interleukin-1 alpha and interleukin-2. 1992 Transplant. Proc. pmid:1371624
Jin MB et al. Protective effect of FK 506 on hepatic energy metabolism in warm ischemic canine livers induced by total hepatic vascular exclusion. 1996 Transplant. Proc. pmid:8623243
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Bond MMK et al. Cyclosporine Versus Tacrolimus: Which Calcineurin Inhibitor Has Influence on Cytomegalovirus Infection in Cardiac Transplantation? 2018 Transplant. Proc. pmid:29661443
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Liu WT et al. In vitro generation of tacrolimus metabolites and their detection in whole blood. 1998 Transplant. Proc. pmid:9636590
Jiang H and Kobayashi M Differences between cyclosporin A and tacrolimus in organ transplantation. 1999 Transplant. Proc. pmid:10455942
Sekido H et al. Successful conversion from cyclosporine to tacrolimus for immunosuppression. 2000 Transplant. Proc. pmid:11120096
Ali MN et al. Case series: hemolytic uremic syndrome--another cause of transplant dysfunction. 2013 Transplant. Proc. pmid:24182801
Koyamada N et al. Strategy for chronic rejection in recipient of living-related liver transplantation. 2000 Transplant. Proc. pmid:11120102
Friemann S et al. Conversion to tacrolimus in hyperlipidemic patients. 1999 Transplant. Proc. pmid:10576042
Kohnle M et al. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia. 1999 Transplant. Proc. pmid:10576043
Batista F et al. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation. 2012 Transplant. Proc. pmid:23146461
Santos L et al. New-onset diabetes after transplantation: drug-related risk factors. 2012 Transplant. Proc. pmid:23146462
Watanabe K et al. Synergistic effect of short-term fractionated lymphoid irradiation with initial high doses of FK506 on the induction of tolerance to kidney allografts in dogs. 1998 Transplant. Proc. pmid:9474940
Hu RH et al. Effects of and predictors for tacrolimus rescue therapy among renal transplant patients under cyclosporine-based immunosuppression. 2004 Transplant. Proc. pmid:15518757
Asano T et al. Increased tacrolimus trough levels in association with severe diarrhea, a case report. 2004 Transplant. Proc. pmid:15518758
Woodle ES et al. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. 1996 Transplant. Proc. pmid:8623495
Rao P et al. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. 1991 Transplant. Proc. pmid:1721301
Ichimaru N et al. Risk factors and incidence for lipid abnormalities in kidney transplant patients. 2015 Transplant. Proc. pmid:25891708
DiLella AG and Craig RJ Characterization of the human FKBP-12 gene and related pseudogenes. 1991 Transplant. Proc. pmid:1721302
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Mucha K et al. 36-month follow-up of 75 renal allograft recipients treated with steroids, tacrolimus, and azathioprine or mycophenolate mofetil. 2003 Transplant. Proc. pmid:14529880
Ushigome H et al. Two cases of tacrolimus-induced alopecia following kidney transplantation. 1999 Transplant. Proc. pmid:10578326
Jacob DA et al. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. 2005 Transplant. Proc. pmid:15919432
Wilusz M et al. Effect of immunosuppressive therapy on the serum fatty acids of phospholipids fraction in patients after heart transplantation. 2014 Transplant. Proc. pmid:25380928
Huang CT et al. Higher Variability of Tacrolimus Trough Level Increases Risk of Acute Rejection in Kidney Transplant Recipients. Transplant. Proc. pmid:27569931
Choi SJ et al. Tacrolimus-induced apoptotic signal transduction pathway. 2008 Transplant. Proc. pmid:18929848
Tannuri AC et al. Effects of immunosuppressants on hepatocyte cell mitosis during liver regeneration in growing animal models of partial hepatectomy. 2008 Transplant. Proc. pmid:18589165
Loh PT et al. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. 2008 Transplant. Proc. pmid:18589174
Lee TK et al. Bacterial translocation and the role of postoperative selective bowel decontamination in small intestinal transplantation. 1994 Transplant. Proc. pmid:7518154
Santiago SF et al. Effect of short-term immunosuppressive therapy with FK 506 or CyA on the donor in small intestine allotransplantation in rats. 1992 Transplant. Proc. pmid:1376520
Tanaka M et al. Effect of anticomplement agent K-76 COOH in hamster-to-rat and guinea pig-to-rat xenotransplantation. 1995 Transplant. Proc. pmid:7533392
Winkler M et al. Use of FK 506 for treatment of chronic rejection after liver transplantation. 1991 Transplant. Proc. pmid:1721334
Serrano J et al. Tacrolimus is effective in both dual and triple regimens after liver transplantation. 2002 Transplant. Proc. pmid:12176469
Troisi R et al. Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults? 2002 Transplant. Proc. pmid:12176470
du Toit DF et al. Tacrolimus (FK506) monotherapy provides potent and significant suppression of allogeneic foetal rat pancreatic allograft rejection. 1998 Transplant. Proc. pmid:9865300
Daoud AJ et al. A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus. 1998 Transplant. Proc. pmid:9865303
Altaca G et al. Effect of low-dose calcineurin inhibitors on acute rejection and graft survival. 2002 Transplant. Proc. pmid:12270320
Pohanka E et al. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients. 2005 Transplant. Proc. pmid:15919490
Hansen LJ et al. Early pharmacokinetic profiles of enteral tacrolimus after multivisceral transplantation. 1997 Transplant. Proc. pmid:9142303
Marqués E et al. Development of lymphoproliferative disease after liver transplantation. 2008 Transplant. Proc. pmid:19010169
Squifflet JP et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. 2002 Transplant. Proc. pmid:12176495
Boggi U et al. Neoral versus prograf in simultaneous pancreas-kidney transplantation with portal venous drainage: three-year results of a single-center, open-label, prospective, randomized pilot study. 2005 Jul-Aug Transplant. Proc. pmid:16182772
Kamei T et al. Established intraportal islet allograft is rejected despite the acceptance of donor-specific second cardiac allograft. 1992 Transplant. Proc. pmid:1281579
Offner G et al. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. 1991 Transplant. Proc. pmid:1721366
Kociszewska-Najman B et al. Congenital Infections in Neonates of Women With Liver or Kidney Transplants. 2016 Transplant. Proc. pmid:27496446
Imai K et al. Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. 1991 Transplant. Proc. pmid:1703347
Molmenti E et al. Noncompliance after pediatric liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083164
Watanabe Y et al. Enteric absorption of FK 506: estimation by a block liver perfusion technique in rats. 1998 Transplant. Proc. pmid:9838656
Wada Y et al. Expression of the transcriptional factor egr-1/BTEB2 in cardiac xenograft vascular remodeling. 2000 Transplant. Proc. pmid:10936371
Li W et al. High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123209
Sharma A et al. Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression. 2008 Transplant. Proc. pmid:18790252
Schumacher G et al. Neurologic symptoms improve in patients with Wilson's disease despite immunosuppression. 1996 Transplant. Proc. pmid:8962200
Beaunoyer M et al. Low-dose tacrolimus, trough-monitored mycophenolate mofetil, and planned steroid withdrawal for cadaveric kidney transplantation: a single center experience. 2002 Transplant. Proc. pmid:12176540
Akutsu N et al. Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients. 2008 Transplant. Proc. pmid:18790253
Boots JM et al. Risk of adrenal insufficiency with steroid maintenance therapy in renal transplantation. 2002 Transplant. Proc. pmid:12176541
Masaki Y et al. Cellular basis of acquired immunologic tolerance following total bowel transplantation in rats. I. Relation between donor lymphocyte chimerism and host-cell-mediated immunity. 1995 Transplant. Proc. pmid:7536971
Watanabe K et al. Prolongation effect of a small dose of FK506, cyclosporine, or azathioprine on renal allografts in dogs treated with fractionated lymphoid irradiation and donor bone marrow cell infusion. 1989 Transplant. Proc. pmid:2468213
Eidelman BH et al. Neurologic complications of FK 506. 1991 Transplant. Proc. pmid:1721398
Sakamoto K et al. Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506. 1989 Transplant. Proc. pmid:2468222
Janezic AL et al. Alternatively spliced variants of IL-2 mRNA in sequential transplant kidney core needle biopsies. 2001 Feb-Mar Transplant. Proc. pmid:11266873
Falconer SJ et al. Conversion from twice-daily to once-daily tacrolimus in simultaneous pancreas-kidney transplant patients. 2014 Transplant. Proc. pmid:24935313
Chiba K et al. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. 1999 Feb-Mar Transplant. Proc. pmid:10083549
Kimura O et al. Influence of bombesin on the intestinal mucosal immunologic response under immunosuppression. 2000 Transplant. Proc. pmid:10995942
Armenti VT et al. Pregnancy outcomes in female renal transplant recipients. 1998 Transplant. Proc. pmid:9723259
Gibelli NE et al. Sirolimus in pediatric liver transplantation: a single-center experience. 2009 Transplant. Proc. pmid:19376384
Kamar N et al. Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. 2004 Transplant. Proc. pmid:15621141
Dette K et al. Daclizumab and ATG versus ATG in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous [correction of simultaneus] pancreas-kidney transplantation: analysis of early outcome. 2002 Transplant. Proc. pmid:12176624
Rintala JM et al. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression. 2006 Transplant. Proc. pmid:17175234
de Bruin RW et al. Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721429
Kawabe A et al. Anti-adhesion (anti-ICAM-1 and anti-LFA-1) therapy in a rat pancreas transplantation model. 1996 Transplant. Proc. pmid:8658893
Ishikawa S et al. Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney Transplantation: A Case Report. 2018 Transplant. Proc. pmid:29661455
Goto T et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. 1987 Transplant. Proc. pmid:2445072
Del Castillo D Analysis of primary and recurrent rejection following renal transplantation in a large, comparative, multicentre trial. 2001 Feb-Mar Transplant. Proc. pmid:11267283
Busque S et al. Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267285
Pirsch JD Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic. 1998 Transplant. Proc. pmid:9723448
Antoine C et al. Vascular microthrombosis in renal transplant recipients treated with tacrolimus. 1998 Transplant. Proc. pmid:9745577
Fritsche L et al. Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function. 1998 Transplant. Proc. pmid:9723451
Fornairon S et al. Can we improve the results of simultaneous pancreas-kidney transplantation? 1998 Transplant. Proc. pmid:9745580
Demir T et al. Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy. 2015 Transplant. Proc. pmid:26093731
Carrieri G et al. Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. 1991 Transplant. Proc. pmid:1721460
Deguchi K et al. Effects of FK 506 on acute experimental allergic encephalomyelitis. 1991 Transplant. Proc. pmid:1721461
Spada M et al. A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis. 2001 Feb-Mar Transplant. Proc. pmid:11267495
Gotsman I et al. Effect of peripheral immune tolerance on liver-associated lymphocytes expressing NK1.1. 2000 Transplant. Proc. pmid:10856569
Girman P et al. Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. 2010 Jul-Aug Transplant. Proc. pmid:20692391
Socci C et al. Pancreata from pediatric donors restore insulin independence in adult insulin-dependent diabetes mellitus recipients. 2010 Jul-Aug Transplant. Proc. pmid:20692410
Kumano K et al. FK 506-induced nephrotoxicity in rats. 1991 Transplant. Proc. pmid:1703696